Indivior Provides Update on Aelis Farma's Phase 2B Cannabis Study
Indivior PLC (Nasdaq/LSE: INDV) has shared an important update regarding the results from Aelis Farma's recent Phase 2B clinical trial of AEF0117. This study aimed to evaluate the effectiveness and safety of AEF0117 for individuals dealing with Cannabis Use Disorder (CUD), a condition marked by problematic cannabis use that leads to significant impairment or distress.
Objectives and Findings of the Study
The trial set out to achieve two main objectives: first, to show that administering AEF0117 (at doses of 0.1, 0.3, and 1 mg once daily over a 12-week period) would significantly reduce cannabis consumption among participants; and second, to determine effective dosage levels and endpoints for future studies. Unfortunately, the results from this Phase 2B trial indicated that neither the primary goal—reducing cannabis use to one day or less per week—nor the secondary goals related to abstinence were met.
Notably, 84% of the participants were identified as having severe CUD, highlighting the complexity of this patient group and the challenges involved in treatment. Despite the disappointment over the unmet endpoints, these findings emphasize the need for further research into the various subpopulations affected by CUD.
Implications for Indivior
In its strategic partnership with Aelis Farma, Indivior held an exclusive option to acquire global rights for AEF0117. However, given the current study results, Indivior has decided to postpone exercising this option until more positive clinical data is available. This cautious stance reflects a commitment to patient safety and the need to confirm the effectiveness of potential treatments before making further investments.
Looking Ahead
This update includes important forward-looking statements regarding AEF0117 and its potential applications. Indivior recognizes the inherent risks and uncertainties involved in drug development, as actual results may differ significantly from expectations due to various factors, including market conditions and regulatory changes.
About Indivior
Indivior is a prominent global pharmaceutical company focused on transforming the treatment landscape for substance use disorders. Through the development of innovative medications, the company aims to ensure that patients worldwide have access to evidence-based therapies that address chronic substance use disorders and co-occurring mental health issues.
Based in Richmond, VA, Indivior employs over 1,000 individuals and offers its products in more than 30 countries. As developers of treatments for opioid use disorder, Indivior is dedicated to expanding its portfolio to include new candidates that may address additional chronic conditions.
Frequently Asked Questions
What was the main focus of the Phase 2B trial?
The trial primarily focused on assessing the efficacy and safety of AEF0117 in patients seeking treatment for Cannabis Use Disorder.
What were the outcomes of this clinical study?
The study did not meet its primary and secondary endpoints, indicating challenges in effectively demonstrating a reduction in cannabis use.
What does Indivior plan to do following these results?
Indivior currently does not plan to exercise its option for AEF0117 until further favorable clinical data becomes available.
How does this impact Indivior's drug development strategy?
This situation highlights the cautious approach Indivior takes in its drug development strategy, focusing on safety and efficacy before proceeding with licensing.
What is Indivior's mission?
Indivior’s mission is to change patients' lives by ensuring access to effective treatments for substance use disorders globally.
